Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous BM-MSCs in Chronic Pancreatitis Patients Undergoing TP-IAT
NCT02384018Phase 1Completed
- Sponsor
- Medical University of South Carolina
- Start
- Dec 2014
- Primary completion
- Jun 2016
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of autologous mesenchymal stromal cell in chronic pancreatitis (CP) and diabetes mellitus (DM) (2 arms), sponsored by Medical University of South Carolina. Primary endpoint: C-peptide level after mixed meal tolerance test at 12 months. Started Dec 2014; status: completed.
02
Drugs
autologous mesenchymal stromal cell
03
Conditions
chronic pancreatitis (CP)diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT02384018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02384018.